CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-12. Anything still debated is marked as such rather than presented as settled.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== Mixed === In mixed inhibition the inhibitor may bind to the enzyme whether or not the substrate has already bound. Hence mixed inhibition is a combination of competitive and noncompetitive inhibition. Furthermore, the affinity of the inhibitor for the free enzyme and the enzyme-substrate complex may differ. By increasing concentrations of substrate [S], this type of inhibition can be reduced (due to the competitive contribution), but not entirely overcome (due to the noncompetitive component). Although it is possible for mixed-type inhibitors to bind in the active site, this type of inhibition generally results from an allosteric effect where the inhibitor binds to a different site on an enzyme. Inhibitor binding to this allosteric site changes the conformation (that is, the tertiary structure or three-dimensional shape) of the enzyme so that the affinity of the substrate for the active site is reduced. These four types of inhibition can also be distinguished by the effect of increasing the substrate concentration [S] on the degree of inhibition caused by a given amount of inhibitor. For competitive inhibition the degree of inhibition is reduced by increasing [S], for noncompetitive inhibition the degree of inhibition is unchanged, and for uncompetitive (also called anticompetitive) inhibition the degree of inhibition increases with [S].
Since 1921, the Toronto Transit Commission (TTC) gradually expanded its public transportation network to Scarborough. Today, it operates bus and rapid transit routes in the district. Line 2 Bloor–Danforth has three subway stations in Scarborough: Victoria Park, Warden, and Kennedy, the current eastern terminus. In 1985, the Government of Ontario opened the Scarborough RT, an above-ground light metro line that operated between Kennedy station at its west and McCowan Road at its east. In 2023, the line shut down permanently due to aging Infrastructure which also caused a derailment earlier that year. Construction of an extension of Line 2 further east into Scarborough started in June 2021 and is expected to be complete around 2030. The line will be extended 7.8 kilometres from Kennedy station with stations at McCowan Road-Lawrence Avenue, Scarborough Centre, and McCowan Road-Sheppard Avenue. Opened in February 2026, Line 5 Eglinton is a light rail line with its eastern terminus at Kennedy station. The City of Toronto is also proposing another light rail line known as the Eglinton East LRT that is planned to operate from Kennedy station to the University of Toronto Scarborough. Seven rail stations also provide access to two commuter rail lines operated by GO Transit. The Lakeshore East line runs across the south end of the district with Rouge Hill GO Station, Guildwood GO Station, Eglinton GO Station, and Scarborough GO Station running from east to west.
=== Continuing Claim === His only son, Ernest Augustus, Crown Prince of Hanover, inherited the claim upon George's death in 1878. Ernest Augustus was also first in line to the throne of the Duchy of Brunswick, whose rulers had been a junior branch of the House of Hanover. In 1884, that branch became extinct with the death of William, a distant cousin of Ernest Augustus. Since Ernest Augustus refused to renounce his claim to annexed Hanover, the Bundesrat of the German Empire ruled that he would disturb the peace of the empire if he ascended the throne of Brunswick. As a result, Brunswick was ruled by a regency until 1913, when his son, also named Ernest Augustus, married the German Emperor's daughter, Princess Viktoria Luise and swore allegiance to the German Empire. The Duke then renounced his claim to Brunswick in favour of his son, and the Bundesrat allowed the younger Ernest Augustus to take possession of Brunswick as a kind of dowry compensation for Hanover. The German-Hanoverian Party, which at times supported secession from the Reich, demanded a separate status for the province in the Reichstag. The party existed until banned by the Nazi government.
== Related compounds == N-Methyliminodiacetic acid (MIDA), the N-methyl derivative of IDA Imidodiacetic acid, the amino diacetic acid N-(2-Carboxyethyl)iminodiacetic acid, a more biodegradable analogue of NTA N-hydroxyiminodiacetic acid (HIDA), HON(CH2CO2H)2 (registry number = 87339-38-6) See HIDA scan.
Sources: en.wikipedia.org
== Insulin == Agonists: Chaetochromin (4548-G05) Insulin-like growth factor 1 Insulin-like growth factor 2 Insulin Insulin aspart Insulin degludec Insulin detemir Insulin glargine Insulin glulisine Insulin lispro Mecasermin Mecasermin rinfabate Antagonists: BMS-754807 S661 S961 Kinase inhibitors: Linsitinib Antibodies: Xentuzumab (against IGF-1 and IGF-2)
== Adverse effects == Although avanafil is generally well tolerated, dose dependent adverse effects can occur. The most common adverse effects include headache, flushing, nasopharyngitis, nasal congestion, and back pain. While it is also uncommon, there is a potential for visual disturbances to occur in patients, as well as hearing impairment.
=== Acquisitions === In 1989, after a four-month legal dispute to avoid a takeover, Church's Chicken became the second-largest chicken restaurant chain when it was acquired by Popeyes for $330 million. The acquisition court documents stated that Church's Chicken would close 250 of its restaurants, "keep 92 with the Church's name, rename 303 others as Popeyes and sell 440 others for about $160 million over the next four years". Merrill Lynch and a group of banks led by Canadian Imperial financed the acquisition. In 1992, Popeyes' parent company, Al Copeland Enterprises, Inc., was forced to file chapter 11 bankruptcy for the more than $400 million debt it owed its creditors for the Church's Chicken buyout. In 1993, Al Copeland Enterprises, Inc. was renamed AFC Enterprises, Inc., or America's Favorite Chicken, and became the parent company of Church's Chicken and Popeyes. In 2004, Arcapita bought Church's Chicken from AFC Enterprises, Inc., and former Domino's Pizza and Little Caesars executive Harsha Agadi became president and CEO of Church's Chicken. In 2005, because Arcapita invests in companies that respect Shari'ah principles, it removed pork products from the Church's Chicken menu. In 2007, AFC Enterprises, Inc. filed a lawsuit against Church's Chicken and former franchise group CVI Company, for allegedly colluding to breach Popeyes' franchise, development and guaranty agreements with CVI, when "Church's [Chicken] bought all 10 of CVI's Popeyes' restaurants and converted most of them to the Church's Chicken brand".
The territory of Germany is divided into five terrestrial ecoregions: Atlantic mixed forests, Baltic mixed forests, Central European mixed forests, Western European broadleaf forests, and Alps conifer and mixed forests. As of 2016, 51% of Germany's land area is devoted to agriculture, while 30% is forested and 14% is covered by settlements or infrastructure. Plants and animals include those generally common to Central Europe. According to the National Forest Inventory, beeches, oaks, and other deciduous trees constitute just over 40% of Germany's forests; roughly 60% are conifers, particularly spruce and pine. There are many species of ferns, flowers, fungi, and mosses. Wild animals include roe deer, wild boar, mouflon (a subspecies of wild sheep), fox, badger, hare, Eurasian lynx, wolves, alpine ibex, and small numbers of the Eurasian beaver. The blue cornflower was once a German national symbol. The 16 national parks in Germany include the Jasmund National Park, the Vorpommern Lagoon Area National Park, the Müritz National Park, the Wadden Sea National Parks, the Harz National Park, the Hainich National Park, the Black Forest National Park, the Saxon Switzerland National Park, the Bavarian Forest National Park and the Berchtesgaden National Park. In addition, there are 17 Biosphere Reserves, and 105 nature parks. More than 400 zoos and animal parks operate in Germany. The Berlin Zoo, which opened in 1844, is the oldest in Germany, and claims the most comprehensive collection of species in the world.
=== Other topics === Other foundational ethical considerations include privacy, confidentiality, accurate and complete medical records, electronic health records, disclosure, and informed decision-making and consent. Electronic health records have been shown to improve patient care but have risks including data breaches and inappropriate and/or unauthorized disclosure of protected health information. Withholding information from a patient is typically seen as unethical and in violation of a patient's right to make informed decisions. However, in situations where a patient has requested not to be informed or to have the information provided to a second party or in an emergency situation in which the patient does not have decision-making capacity, withholding information may be appropriate.
Sources: en.wikipedia.org
=== MasSpec Pen analysis mechanism === The MasSpec Pen, initially described in 2017, is a solvent-based ambient ionization technique but differs from its predecessors due to the handheld nature of the device, allowing analysis of samples distant from the mass spectrometer in a geometry independent manner. The MasSpec Pen used a probe that can be manipulated by hand to direct the analysis. To use the system, the tip of the 'pen' is placed in contact with the surface to be sampled and the user triggers the initiation of a sampling procedure by pressing an integrated foot pedal. This signals a syringe pump to deliver a small aliquot of solvent through a polymer tube to a reservoir at the tip of the 'pen' that remains in contact with the sample. Analytes are then extracted from the sample into the solvent droplet by a solid-liquid extraction mechanism. After a 3 second extraction period, the droplet is aspirated into the mass spectrometer using the vacuum from the mass spectrometer as the vacuum source. Once inside the mass spectrometer, the analytes within the solvent droplet are de-solvated and ionized via an inlet ionization mechanism. The ionized molecules are then analyzed by the mass spectrometer analyzer and the mass spectrum resulting is generated.
The exact definition of "vegetable" may vary simply because of the many parts of a plant consumed as food worldwide—roots, stems, leaves, flowers, fruits, and seeds. The broadest definition is the word's use adjectivally to mean "matter of plant origin". More specifically, a vegetable may be defined as "any plant, part of which is used for food", a secondary meaning then being "the edible part of such a plant". A more precise definition is "any plant part consumed for food that is not a fruit or seed, but including mature fruits that are eaten as part of a main meal". Falling outside these definitions are edible fungi (such as edible mushrooms) and edible seaweed which, although not parts of plants, are often treated as vegetables.
=== Lidar eye-tracking in LASIK === In the 1980s, NASA developed LADAR (for Laser RADAR, now more commonly called Lidar) technology for autonomous rendezvous and docking of space vehicles to service satellites. LASIK surgeons of the time happened to have a problem: patients make involuntary eye movements as frequently as 100 times per second, so the LASIK machine must follow the eye movement to accurately reshape the cornea, the clear front surface of the eye, using a laser. Existing video trackers were too slow, causing interruptions when tracking is lost. The LADARVision 4000, approved in 1998, automatically tracks eye movements at a rate of 4,000 times per second while reshaping the cornea. Lidar is also used in military and NASA-sponsored research for applications in strategic target tracking and weapons firing control.
After his release from jail, Colonel Rhodes immediately joined his brother Cecil and the British South Africa Company in the Second Matabele War taking place just north of the Transvaal in Matabeleland. Cecil Rhodes was forced to resign as Prime Minister of Cape Colony in 1896 due to his apparent involvement in planning and assisting in the raid; he also, along with Alfred Beit, resigned as a director of the British South Africa Company. Jameson's raid had depleted Matabeleland of many of its troops and left the whole territory vulnerable. Seizing on this weakness, and a discontent with the British South Africa Company, the Ndebele revolted during March 1896 in what is now celebrated in Zimbabwe as the First War of Independence, the First Chimurenga, but it is better known to most of the world as the Second Matabele War. The Shona joined them soon thereafter. Hundreds of European settlers were killed within the first few weeks of the revolt and many more would die over the next year and a half. With few troops to support them, the settlers had to quickly build a laager in the centre of Bulawayo on their own. Against over 50,000 Ndebele held up in their stronghold of the Matobo Hills the settlers mounted patrols under such people as Burnham, Baden-Powell, and Selous. It would not be until October 1897 that the Ndebele and Shona would finally lay down their arms.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.